A Phase II Study of ZT002 Injection With Subjects With Overweight or Obesity

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

December 30, 2025

Conditions
Overweight or Obesity
Interventions
DRUG

ZT002 Injection

Administered SC

DRUG

ZT002 Placebo

Administered SC

Trial Locations (16)

100044

Peking University First Hospital, Beijing

Peking University People's Hospital, Beijing

124000

Genertec Liaoyou Gem Flower Hospital, Panjin

134000

Tonghua Central Hospital, Tonghua

150001

The Fourth Affiliated Hospital Harbin Medical University, Harbin

210000

Nanjing Jiangning Hospital, Nanjing

212000

Affiliated Hospital of Jiangsu University, Zhenjiang

250000

Central Hospital Affiliated to Shandong First Medical University, Jinan

255400

Zibo Municipal Hospital, Zibo

471000

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang

471002

Luoyang Third People's Hospital, Luoyang

473000

The First Affiliated of Nanyang Medical College, Nanyang

710000

Xi'an Daxing Hospital, Xi’an

056002

Handan First Hospital, Handan

065000

Hebei Petro China Cental Hospital, Langfang

066000

First Hospital of Qinhuangdao, Qinhuangdao

All Listed Sponsors
lead

Beijing QL Biopharmaceutical Co.,Ltd

INDUSTRY